Trefoil factor 2 vs Larazotide
Head-to-head comparison of Trefoil factor 2 (Trefoil factor 2 (Spasmolytic Polypeptide)) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Trefoil factor 2 | Larazotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Trefoil factor 2 (Spasmolytic Polypeptide) | Larazotide acetate (AT-1001) |
| Molecular Weight | ≈11–12 kDa | N/A |
| Half-Life | Unknown | short; designed for local gut action |
| Amino Acids | 106 | 8 |
| Typical Dose | none established | 0.5-4 mg TID (clinical studies) |
| Route | oral/enteral|research-only | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 40 |
| Research Status | Pre-clinical | Clinical |
Trefoil factor 2 Benefits
- ✓epithelial restitution
- ✓barrier protection
- ✓ulcer healing
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Trefoil factor 2 Dosing
No established clinical dose|preclinical only
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Trefoil factor 2 Side Effects
- ⚠limited human data
- ⚠theoretical growth-factor concerns
- ⚠GI discomfort
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Trefoil factor 2
TFF2 strengthens mucus-barrier repair and epithelial restitution after gastric injury in experimental systems, making it a well-known gastric-protective peptide.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.